Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier

• Main Authors: Nejat Düzgüneş, Melike Sessevmez, Metin Yildirim
• Format: Article
• Language: English
• Published: MDPI AG 2021-01-01
• Series: Pharmaceuticals
• Subjects: lytic infection; antibiotic-resistance; <i>Mycobacterium tuberculosis</i>; <i>Acinetobacter baumannii</i>; <i>Pseudomonas aeruginosa</i>; phage production
• Online Access: https://www.mdpi.com/1424-8247/14/1/34

Antibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include <i>Acinetobacter</i>, Enterobacterioceae, <i>Pseudomonas</i>, <i>Staphylococcus</i> and <i>Mycobacterium</i>. Alternative treatment methods are, thus, necessary to treat such infections. Bacteriophages are viruses of bacteria. In a lytic infection, the newly formed phage particles lyse the bacterium and continue to infect other bacteria. In the early 20th century, d’Herelle, Bruynoghe and Maisin used bacterium-specific phages to treat bacterial infections. Bacteriophages are being identified, purified and developed as pharmaceutically acceptable macromolecular “drugs,” undergoing strict quality control. Phages can be applied topically or delivered by inhalation, orally or parenterally. Some of the major drug-resistant infections that are potential targets of pharmaceutically prepared phages are <i>Pseudomonas aeruginosa</i>, <i>Mycobacterium tuberculosis</i> and <i>Acinetobacter baumannii</i>.